✦ LIBER ✦
Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
✍ Scribed by Moroney, J.; Fu, S.; Moulder, S.; Falchook, G.; Helgason, T.; Levenback, C.; Hong, D.; Naing, A.; Wheler, J.; Kurzrock, R.
- Book ID
- 118020404
- Publisher
- American Association for Cancer Research
- Year
- 2012
- Tongue
- English
- Weight
- 305 KB
- Volume
- 18
- Category
- Article
- ISSN
- 1078-0432
No coin nor oath required. For personal study only.